(To see other currencies, click on price)
MORE ABOUT THIS BOOK
Main description:
Tumor necrosis factor (TNF) superfamily is a rapidly growing family of cytokines that interacts with a corresponding superfamily of receptors. Liga- receptor interactions of this superfamily are involved in numerous biological processes ranging from hematopoiesis to pleiotropic cellular responses, including activation, proliferation, differentiation, and apoptosis. The particular response depends on the receptor, the cell type, and the concurrent signals received by the cell. Worldwide interest in the TNF field surged dramatically early in 1984 with the cloning and defining of the profound cellular effects of the first member of this family, TNF . Subsequently, the major influence of TNF on the development and functioning of the immune system was established. Today, over 20 human TNF ligands and their more than 30 corresponding receptors have been identified. Few receptors still remain orphans. What has emerged over the years is that most TNF ligands bind to one distinct receptor and some of the TNF ligands are able to bind to multiple TNF receptors, explaining to some extent the apparent disparity in the number of TNF receptors and ligands. Yet, in spite of some redundancy in TNF ligand/receptor interactions, it is clear that in vivo spatial, temporal, and indeed cell- and tissue-specific expression of both ligands and their receptors are important factors in determining the precise nature of cellular, physiological and pathological processes they control. TNF superfamily has been the most highly investigated area of basic medical research for over two decades.
Contents:
1. Overview of TNF Superfamily: A Chest Full of Potential Therapeutic Targets
Iqbal S. Grewal Abstract Introduction Therapeutic Potential of TNF Superfamily for Anticancer Treatment Therapeutic Potential of TNF Superfamily for Autoimmune and Inflammatory Disease Challenges for Targeting TNF Superfamily Members Summary and Conclusions 2. Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges
Che-Leung Law and Iqbal S. Grewal Abstract Introduction CD40L Expression in Autoimmune and Inflammatory Conditions CD40-Mediated Inflammatory Reaction Genetic Evidence for the Contribution of CD40-CD40L Interaction in Experimental Autoimmune and Inflammatory Diseases Therapeutic Targeting of CD40L: Proof of Concept Preclinical Animal Models of Autoimmunity and Inflammation Clinical Experience with Anti-CD40L Mechanism(s) of Action of Anti-CD40L mAbs: Toxicity versus Efficacy Potential Alternative Therapeutic Approaches Targeting CD40L CD40 Signaling in Transformed Cells CD40 and Cancer Immune Surveillance Characteristics of Anti-CD40 Antibodies Clinical Experience in Therapeutic Targeting of CD40 Considerations for Therapeutics Targeting CD40 Conclusions 3. Targeting TNF for Treatment of Cancer and Autoimmunity
Gautam Sethi, Bokyung Sung, Ajaikumar B. Kunnumakkara and Bharat B. Aggarwal Abstract Discovery of TNF Signaling Mechanism(s) by TNF-a Role of TNF-a in Cancer Role of TNF-a in the Immune System Role of TNF-a in Autoimmune Diseases TNF Inhibitors Natural Products as Inhibitors of TNF Conclusion 4. Targeting of BAFF and APRIL for Autoimmunity and Oncology
Maureen C. Ryan and Iqbal S. Grewal Abstract Introduction The BAFF and APRIL Receptor/Ligand System BAFF and APRIL Regulate Immune Functions BAFF and APRIL in Autoimmunity APRIL and BAFF in Cancer Parallels between Autoimmunity and Cancer New Therapeutics for Autoimmunity and Cancer Future Applications, New Research, Anticipated Developments 5. The Role of FasL and Fas in Health and Disease
Martin Ehrenschwender and Harald Wajant Abstract The FasL-Fas System The FasL-Fas System in Health and Disease Therapeutic Concepts Targeting the FasL-Fas System 6. OX40 (CD134) and OX40L
Michael J. Gough and Andrew D. Weinberg Abstract Expression of OX40 and OX40L Biologic Function of OX40-OX40L Interactions Expression and Role of OX40 and OX40L in Disease Intervention in OX40-OX40L Interaction for Therapy Conclusion 7. Targeting CD70 for Human Therapeutic Use
Tamar Boursalian, Julie McEarchern, Che-Leung Law and Iqbal S. Grewal Abstract Introduction CD70 Expression and Biology CD70 in Autoimmunity CD70 in Oncology Conclusions and Future Directions 8. 4-1BB as a Therapeutic Target for Human Disease
Seung-Woo Lee and Michael Croft Abstract Introduction to Basic Research Expression of 4-1BB and 4-1BBL Therapeutic Effects of Targeting 4-1BB or 4-1BBL Possible Mechanisms of Action of 4-1BB Agonistic Antibodies Concluding Remarks 9. RANK(L) as a Key Target for Controlling Bone Loss
Andreas Leibbrandt and Josef M. Penninger Abstract Overview Basic Characteristics of the RANKL-RANK-OPG Axis Bone Remodeling and the RANKL-RANK-OPG Axis RANK(L) Signaling Pathways RANK(L) Signaling in the Immune System<
PRODUCT DETAILS
Publisher: Springer (Springer-Verlag New York Inc.)
Publication date: December, 2010
Pages: 237
Weight: 463g
Availability: Available
Subcategories: General Issues, Immunology, Oncology, Pharmacology
Publisher recommends
From the same series
